应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
02575 轩竹生物-B
圣诞节后第一个工作日休市 12-24 11:59:05
70.450
-0.300
-0.42%
最高
72.000
最低
69.800
成交量
20.10万
今开
70.000
昨收
70.750
日振幅
3.11%
总市值
364.89亿
流通市值
113.21亿
总股本
5.18亿
成交额
1,424万
换手率
0.13%
流通股本
1.61亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
一周港股牛熊榜 | 东航周涨17%领跑,力勤资源、新华保险强势!曹操出行、商汤深度回调
老虎资讯综合 · 12-19
一周港股牛熊榜 | 东航周涨17%领跑,力勤资源、新华保险强势!曹操出行、商汤深度回调
港股异动|生物医药股上扬,药捷安康涨超17%,昭衍新药涨超9%
老虎资讯综合 · 12-17
港股异动|生物医药股上扬,药捷安康涨超17%,昭衍新药涨超9%
一周港股牛熊榜 | 长飞光纤光缆周内飙34%,AI算力基建热潮推动光通信需求;轩竹生物周升28%,轩悦宁进入医保目录;第一拖拉机周升21%获高盛看好
老虎资讯综合 · 12-12
一周港股牛熊榜 | 长飞光纤光缆周内飙34%,AI算力基建热潮推动光通信需求;轩竹生物周升28%,轩悦宁进入医保目录;第一拖拉机周升21%获高盛看好
港股异动 | 轩竹生物-B(02575)涨超20%再破顶 轩悦宁进入医保目录 两款肿瘤产品年内密集获批
智通财经 · 12-12
港股异动 | 轩竹生物-B(02575)涨超20%再破顶 轩悦宁进入医保目录 两款肿瘤产品年内密集获批
轩竹生物-B再飙16%,股价续刷上市以来新高!该股本周已累涨近40%
老虎资讯综合 · 12-12
轩竹生物-B再飙16%,股价续刷上市以来新高!该股本周已累涨近40%
两款肿瘤产品年内密集获批 从产品力视角看轩竹生物(02575)创新价值
智通财经 · 12-12
两款肿瘤产品年内密集获批 从产品力视角看轩竹生物(02575)创新价值
轩竹生物-B股价创上市以来新高!旗下创新药轩悦宁首次纳入国家基本医保药品目录
老虎资讯综合 · 12-11
轩竹生物-B股价创上市以来新高!旗下创新药轩悦宁首次纳入国家基本医保药品目录
港股异动 | 轩竹生物-B(02575)涨近3% 自研创新药轩悦宁®首次纳入2025国家基本医保目录
智通财经 · 12-10
港股异动 | 轩竹生物-B(02575)涨近3% 自研创新药轩悦宁®首次纳入2025国家基本医保目录
从医保准入打开增量,来看轩竹生物-B(2575.HK)以差异化管线筑牢价值根基
格隆汇 · 12-08
从医保准入打开增量,来看轩竹生物-B(2575.HK)以差异化管线筑牢价值根基
轩竹生物-B(02575):创新药轩悦宁®首次纳入2025国家基本医保目录
智通财经 · 12-08
轩竹生物-B(02575):创新药轩悦宁®首次纳入2025国家基本医保目录
轩竹生物科技(02575)更新11月股份变动月报表,股本维持稳定
公告速递 · 12-04
轩竹生物科技(02575)更新11月股份变动月报表,股本维持稳定
轩竹生物-B盘中异动 股价大涨5.72%报67.500港元
市场透视 · 11-25
轩竹生物-B盘中异动 股价大涨5.72%报67.500港元
轩竹生物-B11月21日主力净流出242.6万元 散户资金买入
市场透视 · 11-21
轩竹生物-B11月21日主力净流出242.6万元 散户资金买入
四环医药(00460.HK):轩竹生物尚未就H股于联交所主板上市及买卖向联交所提出申请
中金财经 · 11-18
四环医药(00460.HK):轩竹生物尚未就H股于联交所主板上市及买卖向联交所提出申请
轩竹生物-B11月18日主力净流出403.6万元 散户资金买入
市场透视 · 11-18
轩竹生物-B11月18日主力净流出403.6万元 散户资金买入
轩竹生物-B(02575)就建议实施H股全流通向中国证监会备案
智通财经 · 11-17
轩竹生物-B(02575)就建议实施H股全流通向中国证监会备案
轩竹生物-B(02575)建议实施H股全流通
智通财经 · 11-14
轩竹生物-B(02575)建议实施H股全流通
轩竹生物-B11月14日遭主力抛售32.6万元
市场透视 · 11-14
轩竹生物-B11月14日遭主力抛售32.6万元
轩竹生物-B11月11日遭主力抛售556.8万元
市场透视 · 11-11
轩竹生物-B11月11日遭主力抛售556.8万元
荣誉 | 轩竹生物荣膺中国证券报“成长价值金牛奖”
轩竹生物 · 11-10
荣誉 | 轩竹生物荣膺中国证券报“成长价值金牛奖”
加载更多
公司概况
公司名称:
轩竹生物-B
所属市场:
SEHK
上市日期:
--
主营业务:
轩竹生物科技股份有限公司是一家根植于中国、具有全球化视野的创新型制药企业,聚焦于消化、肿瘤及非酒精性脂肪性肝炎等重大疾病领域,致力于持续开发并商业化具有核心自主知识产权的1类新药,解决临床上未被满足的治疗需求。公司是一家根植于中国、具有全球化视野的创新型制药企业。
发行价格:
--
{"stockData":{"symbol":"02575","market":"HK","secType":"STK","nameCN":"轩竹生物-B","latestPrice":70.45,"timestamp":1766548745406,"preClose":70.75,"halted":0,"volume":201024,"delay":0,"floatShares":160701996,"shares":517947790,"eps":-1.3700753406482316,"marketStatus":"圣诞节后第一个工作日休市","change":-0.3,"latestTime":"12-24 11:59:05","open":70,"high":72,"low":69.8,"amount":14237477,"amplitude":0.031095,"askPrice":70.55,"askSize":500,"bidPrice":69.8,"bidSize":1000,"shortable":0,"etf":0,"ttmEps":-1.3699078017589972,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766971800000},"marketStatusCode":7,"adr":0,"listingDate":1760457600000,"exchange":"SEHK","adjPreClose":70.75,"openAndCloseTimeList":[[1766539800000,1766548800000]],"volumeRatio":1.305928064172215,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02575","defaultTab":"news","newsList":[{"id":"1165476322","title":"一周港股牛熊榜 | 东航周涨17%领跑,力勤资源、新华保险强势!曹操出行、商汤深度回调","url":"https://stock-news.laohu8.com/highlight/detail?id=1165476322","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1165476322?lang=zh_cn&edition=full","pubTime":"2025-12-19 17:49","pubTimestamp":1766137794,"startTime":"0","endTime":"0","summary":"月内,货邮周转量上升13.30%。据悉,力勤资源是全球领先的镍龙头企业,全面覆盖镍产业链。12月14日,又一利好政策出台。12月9日晚间,中国人寿发布公告称,今年截至11月30日总保费已突破7000亿元。不过,相关公告消息未止曹操出行股价周二续跌。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02577","01336","06666","00020","02575","02245","02630","02643","00670","03858"],"gpt_icon":1},{"id":"1150760712","title":"港股异动|生物医药股上扬,药捷安康涨超17%,昭衍新药涨超9%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150760712","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150760712?lang=zh_cn&edition=full","pubTime":"2025-12-17 10:50","pubTimestamp":1765939813,"startTime":"0","endTime":"0","summary":"轩竹生物涨超5%,银诺医药涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"22a0e03e703ab82b83863db78ab69d04","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02591","02617","06127","02575"],"gpt_icon":0},{"id":"1176090511","title":"一周港股牛熊榜 | 长飞光纤光缆周内飙34%,AI算力基建热潮推动光通信需求;轩竹生物周升28%,轩悦宁进入医保目录;第一拖拉机周升21%获高盛看好","url":"https://stock-news.laohu8.com/highlight/detail?id=1176090511","media":"老虎资讯综合","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176090511?lang=zh_cn&edition=full","pubTime":"2025-12-12 18:12","pubTimestamp":1765534337,"startTime":"0","endTime":"0","summary":"高速光模块、光纤光缆及相关配套设备的需求随之水涨船高。$轩竹生物-B$ 本周累升28.11%,轩悦宁进入医保目录,两款肿瘤产品年内密集获批轩竹生物近日宣布,创新药轩悦宁首次纳入国家基本医保药品目录。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f31f9c4b7b746092dc00ca030c9a8d42","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":"一周港股牛熊榜 | 长飞光纤光缆周内飙34%,AI算力基建热潮推动光通信需求;轩竹生物周升28%,轩悦宁进...","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06127","01072","06869","HSI","09678","02591","01618","00108","02643","00038","02575","HSTECH","HSCEI"],"gpt_icon":1},{"id":"2590265255","title":"港股异动 | 轩竹生物-B(02575)涨超20%再破顶 轩悦宁进入医保目录 两款肿瘤产品年内密集获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2590265255","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590265255?lang=zh_cn&edition=full","pubTime":"2025-12-12 10:09","pubTimestamp":1765505371,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,轩竹生物-B涨超20%,高见93.05港元,再创上市新高。消息面上,轩竹生物近日宣布,创新药轩悦宁首次纳入国家基本医保药品目录。智通财经APP在《两款肿瘤产品年内密集获批 从产品力视角看轩竹生物创新价值》中指出,医药行业价值回归产品力的背景下,轩竹生物2025年两款肿瘤新药获批,完成创新价值关键兑现。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"f31f9c4b7b746092dc00ca030c9a8d42","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380728.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02575"],"gpt_icon":0},{"id":"1150977349","title":"轩竹生物-B再飙16%,股价续刷上市以来新高!该股本周已累涨近40%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150977349","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150977349?lang=zh_cn&edition=full","pubTime":"2025-12-12 09:57","pubTimestamp":1765504633,"startTime":"0","endTime":"0","summary":"12月12日,$轩竹生物-B(02575)$再飙16%,股价续刷上市以来新高,该股本周已累涨近40%;旗下创新药轩悦宁首次纳入国家基本医保药品目录。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"7432cf6f68b776bebe5e689173bcab7f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575","BK1574","BK1191","BK1161"],"gpt_icon":0},{"id":"2590152848","title":"两款肿瘤产品年内密集获批 从产品力视角看轩竹生物(02575)创新价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2590152848","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590152848?lang=zh_cn&edition=full","pubTime":"2025-12-12 08:48","pubTimestamp":1765500512,"startTime":"0","endTime":"0","summary":"在此背景下,轩竹生物在2025年迎来其肿瘤管线的集中兑现期——其自主研发的CDK4/6抑制剂吡洛西利与ALK抑制剂地罗阿克在年内相继获批上市,与早前上市的消化产品安奈拉唑钠,共同构成了驱动公司商业化的“三驾马车”。回溯今年5月,该药已获国家药监局批准两项适应症。对新确诊的晚期患者,一线联用可实现长期疾病控制。结语医药行业价值回归产品力的背景下,轩竹生物 2025 年两款肿瘤新药获批,完成创新价值关键兑现。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"两款肿瘤产品年内密集获批 从产品力视角看轩竹生物(02575)创新价值","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02575"],"gpt_icon":1},{"id":"1111457270","title":"轩竹生物-B股价创上市以来新高!旗下创新药轩悦宁首次纳入国家基本医保药品目录","url":"https://stock-news.laohu8.com/highlight/detail?id=1111457270","media":"老虎资讯综合","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1111457270?lang=zh_cn&edition=full","pubTime":"2025-12-11 13:43","pubTimestamp":1765431788,"startTime":"0","endTime":"0","summary":"12月11日,$轩竹生物-B$涨超10%,股价创上市以来新高!轩竹$生物$旗下创新药轩悦宁首次纳入国家基本医保药品目录。此次医保谈判结果将有助于提高吡洛西利片在患者中的可负担性和可及性,推动药物市场推广和销售规模的提升,进而对轩竹生物的长期经营发展产生积极影响。其已获批的两项适应症均被纳入2025国家基本医保目录,此外,吡洛西利联合芳香化酶抑制剂的一线治疗适应症的上市申请正在审核中。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":0},{"id":"2590308456","title":"港股异动 | 轩竹生物-B(02575)涨近3% 自研创新药轩悦宁®首次纳入2025国家基本医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2590308456","media":"智通财经","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590308456?lang=zh_cn&edition=full","pubTime":"2025-12-10 13:38","pubTimestamp":1765345130,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,轩竹生物-B涨近3%,截至发稿,涨1.98%,报66.95港元,成交额1519.53万港元。消息面上,12月8日,轩竹生物-B发布公告,本公司自主研发的创新药吡洛西利片首次纳入《国家基本医疗保险、生育保险和工伤保险药品目录》。2025国家基本医保目录将于2026年1月1日正式执行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575","BK1161","06978","BK1191","BK1574","159992"],"gpt_icon":0},{"id":"2590653753","title":"从医保准入打开增量,来看轩竹生物-B(2575.HK)以差异化管线筑牢价值根基","url":"https://stock-news.laohu8.com/highlight/detail?id=2590653753","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590653753?lang=zh_cn&edition=full","pubTime":"2025-12-08 17:57","pubTimestamp":1765187833,"startTime":"0","endTime":"0","summary":"近期,2025年国家医保目录调整结果正式揭晓,轩竹生物上演创新药\"双响\"。在创新药行业从\"管线叙事\"转向\"业绩兑现阶段\"的当下,此次医保突破既是轩竹生物商业化的加速键,亦或是解读其管线价值与成长潜力的最佳窗口。其次,安奈拉唑钠的医保续约则为轩竹生物筑牢业绩基本盘。至此,轩竹生物肿瘤与消化的商业化\"三驾马车\"正式成形。在成熟赛道中,轩竹生物的策略并非复刻热门靶点,而是以临床价值深耕挖掘存量空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208175742979638b7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251208175742979638b7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02575"],"gpt_icon":0},{"id":"2589738572","title":"轩竹生物-B(02575):创新药轩悦宁®首次纳入2025国家基本医保目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2589738572","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589738572?lang=zh_cn&edition=full","pubTime":"2025-12-08 12:12","pubTimestamp":1765167154,"startTime":"0","endTime":"0","summary":"智通财经APP讯,轩竹生物-B(02575)发布公告,本公司自主研发的创新药吡洛西利片(商品名:轩悦宁®)首次纳入《国家基本医疗保险、生育保险和工伤保险药品目录( 2025年 )》(2025国家基本医保目录)。 2025国家基本医保目录将于2026年1月1日正式执行。本次医保谈判结果有助于本公司进一步提高轩悦宁®在患者中的可负担性和可及性,有利于进一步推动该药物的市场推广、提升销售规模,对本公司的长期经营发展具有积极影响。本公司将积极配合推进医保政策落地,持续推进医院准入工作、拓展核心市场及扩大市场的覆盖,以期不断提升患者的用药可及性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","02575","159992","BK1161","06978","BK1574"],"gpt_icon":0},{"id":"1133543268","title":"轩竹生物科技(02575)更新11月股份变动月报表,股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1133543268","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133543268?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:36","pubTimestamp":1764837367,"startTime":"0","endTime":"0","summary":"轩竹生物科技股份有限公司于2025年12月4日发布截至2025年11月30日的股份变动月报表。根据公告,报告期内公司股本结构未发生变化,已发行H股数量保持在160,701,996股,未上市普通股数量维持357,245,794股,两项合计517,947,790股。公司本月无新增发行、购回、注销或库藏股活动。公司声明其遵守香港联交所《上市规则》的相关规定,本次月报由联席公司秘书何成明签署。公司同时强调将持续按要求披露后续股份变动情况,以维护投资者对公司资本状况的了解。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02575"],"gpt_icon":0},{"id":"2586308440","title":"轩竹生物-B盘中异动 股价大涨5.72%报67.500港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2586308440","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586308440?lang=zh_cn&edition=full","pubTime":"2025-11-25 09:32","pubTimestamp":1764034332,"startTime":"0","endTime":"0","summary":"2025年11月25日早盘09时32分,轩竹生物-B股票出现异动,股价快速拉升5.72%。截至发稿,该股报67.500港元/股,成交量1.2万股,换手率0.01%,振幅5.56%。资金方面,该股资金流入45.6975万港元,流出6.665万港元。轩竹生物-B股票所在的生物技术行业中,整体涨幅为0.20%。其相关个股中,银诺医药-B、康方生物、轩竹生物-B涨幅较大,振幅较大的相关个股有华康生物医学、银诺医药-B、轩竹生物-B,振幅分别为11.27%、8.69%、4.23%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125093212a4b82bf0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251125093212a4b82bf0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":0},{"id":"2585323129","title":"轩竹生物-B11月21日主力净流出242.6万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2585323129","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585323129?lang=zh_cn&edition=full","pubTime":"2025-11-21 16:15","pubTimestamp":1763712937,"startTime":"0","endTime":"0","summary":"11月21日, 轩竹生物-B股价跌0.63%,报收63.20元,成交金额2171.3万元,换手率0.21%,振幅1.42%,量比0.97。轩竹生物-B今日主力资金净流出242.6万元,上一交易日主力净流入11.5万元。该股近5个交易日下跌1.80%,主力资金累计净流出166.5万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流出270.8万元,其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121161800a7088a3d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251121161800a7088a3d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":0},{"id":"2584385959","title":"四环医药(00460.HK):轩竹生物尚未就H股于联交所主板上市及买卖向联交所提出申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2584385959","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584385959?lang=zh_cn&edition=full","pubTime":"2025-11-18 23:07","pubTimestamp":1763478425,"startTime":"0","endTime":"0","summary":"格隆汇11月18日丨四环医药(00460.HK)公告,内容有关经轩竹生物董事会考虑及批准实施H股全流通的建议,轩竹生物已于2025年11月17日向中国证券监督管理委员会提交备案申请,以按一对一基准将六名股东合共357,245,794股轩竹生物未上市股份转换为H股(占轩竹生物于2025年11月14日已发行股份总数约68.9733%)。\r\n\r\n 于本公告日期,轩竹生物尚未就该等H股于联交所主板上市及买卖向联交所提出申请,且有关执行计划详情尚未落实。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251118/31806223.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02575","BK1515","BK1600","BK1593","00460","BK1191"],"gpt_icon":0},{"id":"2584295244","title":"轩竹生物-B11月18日主力净流出403.6万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2584295244","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584295244?lang=zh_cn&edition=full","pubTime":"2025-11-18 16:15","pubTimestamp":1763453738,"startTime":"0","endTime":"0","summary":"11月18日, 轩竹生物-B股价跌0.63%,报收63.20元,成交金额2198.7万元,换手率0.22%,振幅1.97%,量比1.02。轩竹生物-B今日主力资金净流出403.6万元,上一交易日主力净流入471.1万元。该股近5个交易日下跌2.17%,主力资金累计净流出640.2万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流入3910.5万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118161847a4a9b1e9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251118161847a4a9b1e9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":0},{"id":"2584648040","title":"轩竹生物-B(02575)就建议实施H股全流通向中国证监会备案","url":"https://stock-news.laohu8.com/highlight/detail?id=2584648040","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584648040?lang=zh_cn&edition=full","pubTime":"2025-11-17 16:32","pubTimestamp":1763368334,"startTime":"0","endTime":"0","summary":"智通财经APP讯,轩竹生物-B(02575)公布,于 2025年 11月 17日,公司已向中国证监会提交备案申请,内容有关建议实施H股全流通,以按一对一基准将合共357,245,794股未上市股份转换为H股。待完成所有备案规定(包括向中国证监会备案)并获得所有相关批准(包括联交所批准转换及上市)并遵守所有适用法律、法规及规则后,357,245,794股未上市股份将转换为357,245,794股H股,并将于联交所上市及买卖。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575"],"gpt_icon":0},{"id":"2583575835","title":"轩竹生物-B(02575)建议实施H股全流通","url":"https://stock-news.laohu8.com/highlight/detail?id=2583575835","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583575835?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:32","pubTimestamp":1763109131,"startTime":"0","endTime":"0","summary":"智通财经APP讯,轩竹生物-B(02575)公布,于 2025年11月14日,董事会经考虑及批准实施H股全流通的建议,即将公司六名股东持有的357,245,794股公司未上市股份转换为公司H股(占公司于本公告日期已发行股份总数约68.9733%)。待取得所有相关批准(包括向中国证监会存档)并遵守所有适用法律、法规及规则后,357,245,794股未上市股份将转换为H股,而公司亦将向联交所申请批准该等H股于联交所主板上市及买卖。于本公告日期,公司尚未向中国证监会申请H股全流通。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369299.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02575"],"gpt_icon":0},{"id":"2583509577","title":"轩竹生物-B11月14日遭主力抛售32.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2583509577","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583509577?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:15","pubTimestamp":1763108122,"startTime":"0","endTime":"0","summary":"11月14日, 轩竹生物-B股价跌0.23%,报收63.95元,成交金额2318.9万元,换手率0.23%,振幅2.81%,量比0.92。轩竹生物-B今日主力资金净流出32.6万元,连续6日净流出,上一交易日主力净流出332.5万元。该股近5个交易日下跌2.39%,主力资金累计净流出1402.8万元,其中2个交易日为股价上涨时净流出;近20日主力资金累计净流入4820.8万元,其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114161647a4a10c35&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251114161647a4a10c35&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":0},{"id":"2582352318","title":"轩竹生物-B11月11日遭主力抛售556.8万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582352318","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582352318?lang=zh_cn&edition=full","pubTime":"2025-11-11 16:15","pubTimestamp":1762848954,"startTime":"0","endTime":"0","summary":"11月11日, 轩竹生物-B股价跌2.34%,报收64.65元,成交金额2105.2万元,换手率0.20%,振幅3.55%,量比0.79。轩竹生物-B今日主力资金净流出556.8万元,连续3日净流出,上一交易日主力净流出138.3万元。该股近5个交易日下跌0.92%,主力资金累计净流出500.1万元,其中1个交易日为股价上涨时净流出;近20日主力资金累计净流入6352.1万元,其中净流入天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111116214494fd37ac&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111116214494fd37ac&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":0},{"id":"2582335618","title":"荣誉 | 轩竹生物荣膺中国证券报“成长价值金牛奖”","url":"https://stock-news.laohu8.com/highlight/detail?id=2582335618","media":"轩竹生物","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2582335618?lang=zh_cn&edition=full","pubTime":"2025-11-10 16:39","pubTimestamp":1762763983,"startTime":"0","endTime":"0","summary":"11月8日,由中国证券报主办、新华社新闻信息中心承办的“2025厦门产业发展大会暨金圆集团杯·上市公司(港股)金牛奖颁奖典礼”于厦门成功举行。本次大会上,轩竹生物科技股份有限公司凭借在生物医药领域突出的创新研发能力、强劲的成长潜力与广阔的发展前景,从一众入围企业中脱颖而出,荣膺“成长价值金牛奖”。此次荣获“成长价值金牛奖”,正是对公司创新研发实力、全链条开发能力与高质量成长潜力的最佳印证。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110164155a6ef0747&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110164155a6ef0747&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02575"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xuanzhubio.com","stockEarnings":[{"period":"1week","weight":-0.0147},{"period":"1month","weight":0.1034},{"period":"3month","weight":5.0733},{"period":"ytd","weight":5.0733}],"compareEarnings":[{"period":"1week","weight":0.0137},{"period":"1month","weight":0.004},{"period":"3month","weight":-0.0251},{"period":"6month","weight":0.0632},{"period":"1year","weight":0.2846},{"period":"ytd","weight":0.2871}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"轩竹生物科技股份有限公司是一家根植于中国、具有全球化视野的创新型制药企业,聚焦于消化、肿瘤及非酒精性脂肪性肝炎等重大疾病领域,致力于持续开发并商业化具有核心自主知识产权的1类新药,解决临床上未被满足的治疗需求。公司是一家根植于中国、具有全球化视野的创新型制药企业。","exchange":"SEHK","name":"轩竹生物-B","nameEN":"XUANZHUBIO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"轩竹生物-B(02575)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供轩竹生物-B(02575)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"轩竹生物-B,02575,轩竹生物-B股票,轩竹生物-B股票老虎,轩竹生物-B股票老虎国际,轩竹生物-B行情,轩竹生物-B股票行情,轩竹生物-B股价,轩竹生物-B股市,轩竹生物-B股票价格,轩竹生物-B股票交易,轩竹生物-B股票购买,轩竹生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"轩竹生物-B(02575)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供轩竹生物-B(02575)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}